Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
lurasidone
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Latuda
|
| gptkbp:chemicalFormula |
C22H25N3O2S
|
| gptkbp:clinicalTrials |
short-term treatment
Phase III long-term treatment approved for use in children aged 10-17 studied for efficacy in mixed episodes. studied in over 4000 patients |
| gptkbp:contraindication |
metabolic syndrome
restlessness hyperlipidemia hyperglycemia extrapyramidal symptoms severe hepatic impairment hypersensitivity to lurasidone somnolence neuroleptic malignant syndrome tardive dyskinesia concomitant use of strong CYP3A4 inducers concomitant use of strong CYP3A4 inhibitors |
| gptkbp:dosageForm |
once daily
|
| gptkbp:drugInterdiction |
5-HT2A receptor antagonist
5-HT7 receptor antagonist D2 receptor antagonist alpha-2C adrenergic receptor antagonist oral bioavailability 9% peak plasma concentration in 1-3 hours |
| gptkbp:endOfLife |
18 hours
|
| gptkbp:formFactor |
tablet
|
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:hasPopulation |
children
adults |
| https://www.w3.org/2000/01/rdf-schema#label |
Latuda
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:lastProduced |
2010
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mandates |
major depressive episodes associated with bipolar I disorder
|
| gptkbp:manufacturer |
gptkb:Sunovion_Pharmaceuticals
|
| gptkbp:marketedAs |
2010
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
N05AX
|
| gptkbp:route |
oral
|
| gptkbp:sells |
gptkb:Latuda
|
| gptkbp:sideEffect |
nausea
drowsiness insomnia weight gain akathisia |
| gptkbp:usedFor |
treatment of schizophrenia
treatment of bipolar disorder |
| gptkbp:waterManagement |
urine
|